The share price of Protagonist Therapeutics, Inc. (PTGX) now
Latest session on the 5th of December for
Protagonist Therapeutics, Inc. is positive
Trading Volume: 955467
Open: 18.07 /
High: 19.92 /
Low: 18.07
What analysts predict: $39.4
52-week High/Low: $30.1 / $7.45
50/200 Day Moving Average:
$16.08 / $20.51
This figure corresponds to the Average Price over the previous 50/200 days.
For Protagonist Therapeutics stocks, the 50-day moving average is the support level today.
For Protagonist Therapeutics stocks, the 200-day moving average is the support level today.
Are you interested in Protagonist Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio?
If yes, then on this page you will find useful information about the dynamics of the Protagonist Therapeutics
stock price in 2024, 2025, 2026, 2027, 2028.
How much will one Protagonist Therapeutics share be worth in
2024 - 2028?
When should I take profit in Protagonist Therapeutics stock?
When should I record a loss on Protagonist Therapeutics stock?
What are analysts' forecasts for Protagonist Therapeutics stock?
What is the future of Protagonist Therapeutics stock?
We forecast Protagonist Therapeutics stock performance using neural networks based on historical data on Protagonist Therapeutics stocks.
Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Protagonist Therapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals.
(Next month, 2024, 2025, 2026, 2027 and 2028)
The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Protagonist Therapeutics shares. This happens once a day.
Historical and forecast chart of Protagonist Therapeutics stock
The chart below shows the historical price of Protagonist Therapeutics stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Protagonist Therapeutics stock price can be found in the table below.
Long-term forecasts by years.
“Protagonist Therapeutics, Inc.” is a clinical stage biopharmaceutical company with a peptide technology platform focused on the discovery and development of new chemical entities (NECs) to meet significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. His main focus is on the development of oral peptide formulations that target biological pathways, also targeting commercially available injectable antibodies. PTG-100 is an oral peptide product of an alpha-4-beta-7 (a4b7) integrin antagonist candidate who has completed a phase I clinical trial in normal healthy volunteers (NHVs). PTH-100 is being developed for the treatment of moderate to severe ulcerative colitis (UC). PTG-200 is an oral interleukin-23 (IL-23R) receptor antagonist being developed for the treatment of moderate to severe Crohn’s disease. PTG-300 is an injectable hepcidin mimetic for the treatment of rare conditions associated with iron overload.
Trending Themes in the Healthcare Sector
Protagonist Therapeutics daily forecast for a month
Forecast target price for 12-08-2023: $30.62. Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 2.850%. Pessimistic target level: 30.40 Optimistic target level: 31.29
Forecast target price for 12-09-2023: $30.51. Negative dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 1.717%. Pessimistic target level: 30.17 Optimistic target level: 30.70
Forecast target price for 12-10-2023: $30.74. Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 2.113%. Pessimistic target level: 30.53 Optimistic target level: 31.19
Forecast target price for 12-11-2023: $30.22. Negative dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 4.092%. Pessimistic target level: 29.47 Optimistic target level: 30.72
Forecast target price for 12-12-2023: $31.13. Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 2.579%. Pessimistic target level: 30.86 Optimistic target level: 31.68
Forecast target price for 12-13-2023: $31.78. Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 3.938%. Pessimistic target level: 31.00 Optimistic target level: 32.27
Protagonist Therapeutics information and performance
Protagonist Therapeutics Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, US
Market Capitalization:
1 070 506 000 $
Market capitalization of the Protagonist Therapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula
multiplying the number of PTGX shares in the company outstanding by the market price of one share.
EBITDA:
-152 232 000 $
EBITDA of Protagonist Therapeutics is earnings before interest, income tax and depreciation of assets.
PE Ratio:
None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio:
N/A
Price/earnings to growth
DPS:
N/A
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
DY:
N/A
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS:
-2.61
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY:
N/A
Quarterly Revenue Growth YOY:
-1
Trailing PE:
-
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE:
-
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue:
1002.59
Enterprise Value (EV) /Revenue
EV To EBITDA:
-5.15
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding:
57678000
Number of issued ordinary shares
Shares Float:
N/A
Number of freely tradable shares
Shares Short Prior Month:
N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and,
moreover, are not trading signals.
When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market
as a result of using the information contained on the site.
This website uses cookies to ensure you get the best experience on our website